At least 2 million people in the U.S. acquire serious infections with bacteria that are resistant to one or more of the antibiotics designed to combat them.

More than 23,000 people in the U.S. die each year from antibiotic-resistant infections. Many more die from conditions complicated by an antibiotic-resistant infection.

Source: U.S. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2013.
Acute Bacterial Skin and Skin Structure Infections are 
major reasons for hospitalizations in the United States, affecting millions of people annually.

Source:  Zervos MJ et al, Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012 Feb;50(2):238-45. doi: 10.1128/JCM.05817-11. Epub 2011 Nov 23.

Agency for Healthcare Research and Quality, 2011 data (
MRSA is the most common causative pathogen of hospital-treated Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

It is estimated that MRSA kills more people each year than AIDS/HIV today or the polio epidemic at its peak.

Source:  Zervos MJ et al, Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012 Feb;50(2):238-45. doi: 10.1128/JCM.05817-11. Epub 2011 Nov 23.
There are 320,000 cases of gonorrhea reported to the CDC each year in the U.S. – but the actual incidence is estimated at 820,000 because it is often undiagnosed and/or underreported.
The highest rates of gonorrhea affect girls between the ages of 15-24.  Left untreated, gonorrhea can cause serious health problems, including chronic pelvic pain, life-threatening ectopic pregnancy and infertility. Gonorrhea infection also increases a person’s risk of contracting and transmitting HIV.
Due to drug resistance, treatment options for gonorrhea are limited.  
The Centers for Disease Control (CDC) estimates the potential for a four-fold increase in gonorrhea during the next seven years which could amount to 2.4 million infections and direct lifetime medical costs of $780MM.

1.Bolan, G. (2012). Responding to the Urgent Threat of Antibiotic-Resistant Gonorrhea (PowerPoint slides). Retrieved from NCSDDC website: (Accessed 12/11/2013).

2.U.S. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. Morbidity and Mortality Weekly Report. August 10, 2012 / 61(31);590-594

3. Bolan GA. The Emerging Threat of Untreatable Gonococcal Infection. N Engl J Med. 2012 Feb 9;366(6):485-7

ESKAPE pathogens are the 6 resistant bacteria that are among the most difficult to treat
• Enterococcus faecium
• Staphylococcus aureus
• Klebsiella pneumoniae
• Acinetobacter baumannii
• Pseudomonas aeruginosa
• Enterobacter spp./E. coli

66% of all hospital infections are ESKAPE pathogens.

Source: 1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197(8), 1079-1081 (2008)
Press Releases and News
August 14, 2014
Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy
August 11, 2014
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration
July 24, 2014
Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)